Characteristics of study groups
| Characteristic . | Chronic, n (%) . | Clonal evolution only, n (%) . | Accelerated, no clonal evolution, n (%) . | Accelerated + clonal evolution, n (%) . |
|---|---|---|---|---|
| Total | 295 | 70 | 82 | 51 |
| Age, 60 y or older | 108 (37) | 14 (20) | 25 (30) | 17 (33) |
| Splenomegaly present | 55/293 (19) | 17 (24) | 37 (45) | 27 (53) |
| Hemoglobin, 10 g/dL or greater | 266 (90) | 60 (86) | 47 (57) | 24 (47) |
| White blood cell count, 50 × 109/L or greater | 48 (16) | 9 (13) | 18 (22) | 10 (20) |
| Peripheral blasts, 5% or more | 11 (4) | 2 (3) | 22 (27) | 19 (38) |
| Marrow blasts, 5% or more | 42 (14) | 11 (16) | 38 (47) | 36 (71) |
| Peripheral basophils, 7% or more | 40 (14) | 7 (10) | 36 (44) | 22 (43) |
| Marrow basophils, 5% or more | 47 (16) | 14 (19) | 43 (53) | 29 (57) |
| Platelets, more than 450 × 109/L | 71 (24) | 10 (14) | 29 (35) | 13 (25) |
| Ph at start of therapy greater than 90% | 213/290 (73) | 56 (80) | 72/80 (90) | 45/50 (90) |
| CML duration | ||||
| 12-35 mo | 110 (37) | 26 (37) | 19 (23) | 18 (35) |
| 36 mo or longer | 142 (48) | 34 (49) | 37 (45) | 23 (45) |
| Characteristic . | Chronic, n (%) . | Clonal evolution only, n (%) . | Accelerated, no clonal evolution, n (%) . | Accelerated + clonal evolution, n (%) . |
|---|---|---|---|---|
| Total | 295 | 70 | 82 | 51 |
| Age, 60 y or older | 108 (37) | 14 (20) | 25 (30) | 17 (33) |
| Splenomegaly present | 55/293 (19) | 17 (24) | 37 (45) | 27 (53) |
| Hemoglobin, 10 g/dL or greater | 266 (90) | 60 (86) | 47 (57) | 24 (47) |
| White blood cell count, 50 × 109/L or greater | 48 (16) | 9 (13) | 18 (22) | 10 (20) |
| Peripheral blasts, 5% or more | 11 (4) | 2 (3) | 22 (27) | 19 (38) |
| Marrow blasts, 5% or more | 42 (14) | 11 (16) | 38 (47) | 36 (71) |
| Peripheral basophils, 7% or more | 40 (14) | 7 (10) | 36 (44) | 22 (43) |
| Marrow basophils, 5% or more | 47 (16) | 14 (19) | 43 (53) | 29 (57) |
| Platelets, more than 450 × 109/L | 71 (24) | 10 (14) | 29 (35) | 13 (25) |
| Ph at start of therapy greater than 90% | 213/290 (73) | 56 (80) | 72/80 (90) | 45/50 (90) |
| CML duration | ||||
| 12-35 mo | 110 (37) | 26 (37) | 19 (23) | 18 (35) |
| 36 mo or longer | 142 (48) | 34 (49) | 37 (45) | 23 (45) |